Assignee
KANAPH THERAPEUTICS INC
KR·1 granted patent·9 pending applications·0 citations·filing 2021–2024
Top patents by PatentIndex Score
10 records- 0156US2025368754A1Fusion protein comprising light protein and anti-fap antibody and uses thereofKANAPH THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0255US2023295258A1Fusion protein comprising il-12 and anti-fap antibody, and use thereofKANAPH THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0354US2023295327A1Fusion protein comprising il-12 and anti-cd20 antibody and use thereofKANAPH THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0453US2025144178A1Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agentKANAPH THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0550US12029739B2SHP2 inhibitor and use thereofKANAPH THERAPEUTICS INC·Filed 2024·Granted Jul 9, 2024·0 cites·21 claims
- 0650US2025161271A1Pharmaceutical composition for treating cancer, comprising anticancer agent and novel compound having inhibitory activity with respect to prostaglandin e2 receptorsKANAPH THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0748US2025074974A1Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereofKANAPH THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0846US2024400518A1Sos1 inhibitor and use thereofKANAPH THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0942US2023365582A1Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereofKANAPH THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1042US2023242633A1Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereofKANAPH THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KANAPH THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →